|
FCHO2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.95019999727731E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.15970000269527E-08 |
| Normal-vs-Stage2 |
3.043500E-02 |
| Normal-vs-Stage3 |
6.10349999999871E-05 |
| Normal-vs-Stage4 |
1.761920E-04 |
| Stage1-vs-Stage2 |
7.785700E-02 |
| Stage1-vs-Stage3 |
3.540600E-01 |
| Stage1-vs-Stage4 |
4.285400E-01 |
| Stage2-vs-Stage3 |
3.042800E-01 |
| Stage2-vs-Stage4 |
6.794400E-02 |
| Stage3-vs-Stage4 |
2.332800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.28379999964068E-08 |
| Normal-vs-AfricanAmerican |
8.223800E-04 |
| Normal-vs-Asian |
2.021200E-03 |
| Caucasian-vs-AfricanAmerican |
3.938400E-01 |
| Caucasian-vs-Asian |
9.924800E-01 |
| AfricanAmerican-vs-Asian |
5.184000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.41370000039664E-07 |
| Normal-vs-Female |
7.86480000014578E-08 |
| Male-vs-Female |
3.102000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96390004258973E-09 |
| Normal-vs-Age(41-60Yrs) |
1.83893999999851E-05 |
| Normal-vs-Age(61-80Yrs) |
9.437400E-04 |
| Normal-vs-Age(81-100Yrs) |
1.464740E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.853700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.305800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.330200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.125000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.193600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.672760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.979200E-01 |
| Classical-VS-Follicular |
2.07009999999563E-05 |
| Classical-VS-Other |
5.409000E-01 |
| Classical-VS-Normal |
2.87259993569933E-10 |
| Tall-VS-Follicular |
3.801200E-03 |
| Tall-VS-Other |
7.244000E-01 |
| Tall-VS-Normal |
1.620960E-04 |
| Follicular-VS-Other |
2.354800E-01 |
| Follicular-VS-Normal |
5.456200E-02 |
| Other-VS-Normal |
1.206790E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.139860E-03 |
| Normal-vs-N1 |
1.38820000050721E-07 |
| N0-vs-N1 |
3.70900000000729E-05 |
|
|
